Article
Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation.
Cancer science - 1 Mar 2007
Uchida Akiko, Hirano Seiki, Kitao Hiroyuki, Ogino Atsuko, Rai Kanmei, Toyooka Shinichi, Takigawa Nagio, Tabata Masahiro, Takata Minoru, Kiura Katsuyuki, Tanimoto Mitsune
Abstract excerpt
Patients with pulmonary adenocarcinoma carrying the epidermal growth factor receptor (EGFR) mutation tend to display dramatic clinical response to treatment with the EGFR tyrosine kinase inhibitor gefitinib. Unfortunately, in many cases the cancer cells eventually acquire resistance, and this limits the duration of efficacy. To gain insight into these acquired resistance mechanisms, we first prepared HEK293T cell...
Topics
- Adenocarcinoma
- Antineoplastic Agents
- Cell Line, Tumor
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm
- ErbB Receptors
- Gefitinib
- Genes, ras
- Humans
- Lung Neoplasms